[go: up one dir, main page]

EE04491B1 - (+) - use of norcisapride - Google Patents

(+) - use of norcisapride

Info

Publication number
EE04491B1
EE04491B1 EEP200000014A EEP200000014A EE04491B1 EE 04491 B1 EE04491 B1 EE 04491B1 EE P200000014 A EEP200000014 A EE P200000014A EE P200000014 A EEP200000014 A EE P200000014A EE 04491 B1 EE04491 B1 EE 04491B1
Authority
EE
Estonia
Prior art keywords
norcisapride
intestinal disorders
treating gastro
medicament
preparing
Prior art date
Application number
EEP200000014A
Other languages
Estonian (et)
Inventor
Jan Pieter Heykants Jozef
Adrianus Hendrikus Petrus Megens Antonius
Emiel Gustaaf Meuldermans Willem
Adrianus Jacobus Schuurkes Joannes
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200000014A publication Critical patent/EE200000014A/en
Publication of EE04491B1 publication Critical patent/EE04491B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention concerns (+)-norcisapride, and its pharmaceutically acceptable acid additions salts, a process for preparing said compound, and its use for the manufacture of a medicament for treating gastro-intestinal disorders while avoiding central nervous system effects. Also provided are method of treating gastro-intestinal disorders.
EEP200000014A 1997-07-11 1998-07-07 (+) - use of norcisapride EE04491B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97202161 1997-07-11
EP98200661 1998-03-04
PCT/EP1998/004193 WO1999002496A1 (en) 1997-07-11 1998-07-07 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders

Publications (2)

Publication Number Publication Date
EE200000014A EE200000014A (en) 2000-10-16
EE04491B1 true EE04491B1 (en) 2005-06-15

Family

ID=26146686

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000014A EE04491B1 (en) 1997-07-11 1998-07-07 (+) - use of norcisapride

Country Status (30)

Country Link
US (2) US20030060485A1 (en)
EP (1) EP1000029B1 (en)
JP (1) JP3529102B2 (en)
KR (1) KR100358374B1 (en)
CN (1) CN1196681C (en)
AT (1) ATE251139T1 (en)
AU (1) AU757077B2 (en)
BG (1) BG64824B1 (en)
BR (1) BR9811676A (en)
CA (1) CA2292480A1 (en)
CO (1) CO4940432A1 (en)
CZ (1) CZ296212B6 (en)
DE (1) DE69818678T2 (en)
DK (1) DK1000029T3 (en)
EA (1) EA002362B1 (en)
EE (1) EE04491B1 (en)
ES (1) ES2209190T3 (en)
HR (1) HRP20000004A2 (en)
HU (1) HUP0003078A3 (en)
ID (1) ID24228A (en)
IL (1) IL133225A (en)
MY (1) MY129130A (en)
NO (1) NO315183B1 (en)
NZ (1) NZ502207A (en)
PL (1) PL190296B1 (en)
PT (1) PT1000029E (en)
SK (1) SK284941B6 (en)
TR (1) TR200000020T2 (en)
TW (1) TW553934B (en)
WO (1) WO1999002496A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
KR20060017570A (en) 1998-06-15 2006-02-23 세프라코 아이엔시. Use of optically pure (+)-norcysapride to treat apnea, bulimia, and other diseases
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
IL140117A0 (en) 1998-06-15 2002-02-10 Sepracor Inc Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
DK1200090T3 (en) * 1999-08-03 2013-11-25 Icos Corp Pharmaceutical formulation comprising a beta-carboline and its use in the treatment of sexual dysfunction
CA2410939C (en) * 2000-06-07 2010-02-16 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
AU2002231627A1 (en) * 2000-11-24 2002-06-03 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
AU2002356418A1 (en) * 2001-10-08 2003-04-22 Sun Pharmaceutical Industries Limited An antispasmodic agent spaced drug delivery system
JP2003342186A (en) * 2002-05-24 2003-12-03 Taisho Pharmaceut Co Ltd Oral liquid composition for rhinitis
DK2194053T3 (en) 2004-01-07 2013-07-01 Armetheon Inc Methoxypiperidine derivatives for use in the treatment of gastrointestinal and central nervous system disorders.
US8138204B2 (en) 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20060247180A1 (en) * 2005-04-29 2006-11-02 Bergey James L Purgative composition and uses thereof
KR101351454B1 (en) 2005-08-31 2014-01-14 아메데온, 인코포레이티드 Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
KR20100026641A (en) * 2008-09-01 2010-03-10 동아제약주식회사 Novel benzamide derivative and the preparation thereof
JP7203083B2 (en) * 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド Pharmaceutical composition containing entrectinib
US20210290593A1 (en) * 2018-07-11 2021-09-23 Duke University Use of sustained-release 5-hydroxytryptophan in treating gastrointestinal disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
IL89848A (en) * 1988-04-07 1997-08-14 Sepracor Chiral ester derivatives
TW243449B (en) * 1991-02-15 1995-03-21 Hokuriku Pharmaceutical
TW294595B (en) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
FR2717174B1 (en) * 1994-03-14 1996-05-31 Sanofi Sa Use of piperidinoethyl esters of 4-amino-5-chloro-2-methoxybenzoic acid as 5-HT4 agonists.
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
AU757077B2 (en) 2003-01-30
EA002362B1 (en) 2002-04-25
HRP20000004A2 (en) 2000-12-31
ID24228A (en) 2000-07-13
DE69818678D1 (en) 2003-11-06
NO20000093D0 (en) 2000-01-07
ES2209190T3 (en) 2004-06-16
IL133225A0 (en) 2001-03-19
NO315183B1 (en) 2003-07-28
BG64824B1 (en) 2006-05-31
CN1196681C (en) 2005-04-13
AU8857598A (en) 1999-02-08
WO1999002496A1 (en) 1999-01-21
CN1262675A (en) 2000-08-09
NO20000093L (en) 2000-03-10
SK182999A3 (en) 2000-08-14
CZ296212B6 (en) 2006-02-15
PT1000029E (en) 2004-02-27
JP3529102B2 (en) 2004-05-24
US20030060485A1 (en) 2003-03-27
IL133225A (en) 2005-12-18
TW553934B (en) 2003-09-21
BG103934A (en) 2000-11-30
EP1000029B1 (en) 2003-10-01
HK1025092A1 (en) 2000-11-03
MY129130A (en) 2007-03-30
EA200000057A1 (en) 2000-08-28
JP2000515560A (en) 2000-11-21
EP1000029A1 (en) 2000-05-17
EE200000014A (en) 2000-10-16
PL190296B1 (en) 2005-11-30
US20040176414A1 (en) 2004-09-09
BR9811676A (en) 2000-09-19
ATE251139T1 (en) 2003-10-15
KR100358374B1 (en) 2002-10-25
DE69818678T2 (en) 2004-07-15
DK1000029T3 (en) 2004-02-23
KR20010014027A (en) 2001-02-26
TR200000020T2 (en) 2000-09-21
PL337648A1 (en) 2000-08-28
HUP0003078A2 (en) 2001-01-29
HUP0003078A3 (en) 2002-02-28
CZ461799A3 (en) 2000-05-17
CO4940432A1 (en) 2000-07-24
SK284941B6 (en) 2006-02-02
NZ502207A (en) 2001-08-31
CA2292480A1 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
EE04491B1 (en) (+) - use of norcisapride
MX9707980A (en) 4-aminoquinazoline derivatives.
IS1904B (en) Analogous Methods for Preparation of New (R) -5-Carbamoyl-8-Fluoro-3-N, N-Divided-Amino-3,4-Dihydro-2H-1-Benzopyranes
ZA961074B (en) Chiral Methylphenyloxazolidinones.
YU78302A (en) A piridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
ES2173422T3 (en) DISRECIATION OF TREO-METHYLPHENIDATE.
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
ZA976854B (en) Treatment of psychotic disorders.
PL338147A1 (en) Derivatives of polyhydroxylbutylpyrazine, method of obtaining and drugs containing them
MX9704704A (en) 4-amino-2-ureide-pyrimidin-5-carboxylic acid amides, process for the preparation thereof, medicaments containing these compounds, and their utilization.
ES2147499A1 (en) Carboxylic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds
PL352119A1 (en) Derivatives of aminotetraline for treatment of cardiovascular diseases
MX9604692A (en) Quinoxaline derivatives for treating tinnitus.
TNSN99158A1 (en) How to prevent asthma
IL116262A0 (en) Processes for preparing ranitidine
MX9704621A (en) 4-amino-2-ureide-pyrimidin-5-carboxylic acid amides, process for the preparation thereof, medicaments containing these compounds, and their utilization.
JO2127B1 (en) A method for preventing the onest of asthma
SE9901338D0 (en) Novel process

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20080707